Why the study?
Does ticagrelor improve efficacy and safety compared to clopidogrel in patients with acute coronary syndrome?
Does ticagrelor improve efficacy and safety compared to clopidogrel in patients with acute coronary syndrome?
This article reviews the PLATO trial results and discusses the role of ticagrelor in modern clinical practice guidelines for acute coronary syndrome.
Supports ticagrelor in ACS guidelines; leaves open need for updated comparisons with newer agents.
This article provides an analysis of the results of a large international randomized clinical trial PLATO, in which to learn a new antiplatelet ticagrelor compared with clopidogrel in addition to aspirin in patients with acute coronary syndrome (ACS). Material contains a description of the study design, the main results concerning the efficacy and safety of ticagrelor. In addition, the material presented those parts of modern clinical practice guidelines, which describes the location of ticagrelor in the treatment of ACS and which are modified according to a PLATO study.
No takes yet. Share an insight, caveat, or question.
A. D. Erlih (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: